Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH) Trial: A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening

X
Trial Profile

The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH) Trial: A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capivasertib (Primary) ; Ceralasertib (Primary) ; Fulvestrant (Primary) ; Neratinib (Primary) ; Olaparib (Primary)
  • Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms plasmaMATCH
  • Most Recent Events

    • 09 Dec 2023 Results (n=75) assessing paired baseline and early on treatment ctDNA analysis from cohort E of this trial were presented at the 46th Annual San Antonio Breast Cancer Symposium
    • 07 Jun 2022 Results (n=84) assessing analysis of baseline and end-of-treatment (EOT) ctDNA to identify potential resistance mutations to fulvestrant presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2022 Results (n=75) assessing safety and efficacy from cohort E of this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top